Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw unusually large options trading on Tuesday. Stock traders bought 15,360 call options on the company. This represents an increase of 44% compared to the typical daily volume of 10,636 call options.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.25.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total transaction of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. This represents a 0.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This represents a 0.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 55,341 shares of company stock worth $393,490 over the last ninety days. Corporate insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter valued at about $25,000. GAMMA Investing LLC lifted its stake in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after buying an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the period. Amalgamated Bank grew its position in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares during the last quarter. Finally, KBC Group NV increased its holdings in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $7.49 on Wednesday. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of -4.90 and a beta of 0.85. The firm’s fifty day simple moving average is $6.90 and its 200-day simple moving average is $7.02. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $15.74. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.43) earnings per share. Equities analysts forecast that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.